Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 9/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2864893 | 0.87 | SLC5A1 (0.46) | SLC5A2SLC5A1PLK1SMN1; SMN2 | |
| SCHEMBL27684471 | 0.80 | SLC5A2 (0.53) | SLC5A2SLC5A1SMN1; SMN2 | |
| SCHEMBL2874053 | 0.77 | THRA (0.52) | SLC5A2SLC5A1PLK1MAPTHPGD | |
| SCHEMBL1539339 | 0.77 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL2872112 | 0.77 | ESR1 (0.42) | SLC5A2SLC5A1PLK1KDM4EPTPN1 | |
| SCHEMBL2863706 | 0.76 | SLC5A1 (0.49) | SLC5A2SLC5A1PLK1MAPTHPGD | |
| SCHEMBL17189170 | 0.76 | SLC5A2 (0.56) | SLC5A2SLC5A1ERN1 | |
| SCHEMBL16301967 | 0.75 | NQO1 (0.54) | PLK1MAPTTSHRMAPK1SMN1; SMN2 | |
| SCHEMBL2865173 | 0.75 | SLC5A1 (0.50) | SLC5A2SLC5A1PLK1MAPTHPGD | |
| SCHEMBL2874055 | 0.75 | SLC5A2 (0.51) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101072783-A | Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | SLC5A2 1771/4885SLC5A1 1236/4885PLK1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.